Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies

Medivir
Posted on: 21 Nov 18
Medivir Nominates MIV-828 as a Candidate Drug for the Treatment of Hematological Malignancies

PR Newswire

STOCKHOLM, Sweden, Nov. 21, 2018

STOCKHOLM, Sweden, Nov. 21, 2018 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.

AML arises from cells in the bone marrow that are supposed to develop into normal white blood cells but become cancerous instead. These malignant cells build up in the bone marrow, preventing the development of normal blood cells. Many patients are unable to tolerate current therapies. The preclinical data indicate that MIV-828 may become a better tolerated and more effective medicine for patients with AML and other hematological cancers.

"Patients with AML are urgently in need of more effective and better tolerated drugs, and I strongly believe that MIV-828 has the potential to become a future cornerstone in the therapy of AML and related cancers," said Dr Uli Hacksell, Medivir's Chief Executive Officer. "I would also like to express my appreciation to Medivir's outstanding research team for delivering yet another high quality candidate drug".

For further information, please contact:

Uli Hacksell,
CEO, Medivir AB,
phone: +46 (0)8-5468-3100

Erik Björk,
CFO, Medivir AB,
mobile: +46 (0)72-228-2831

About acute myeloid leukemia (AML)

Around 20,000 US patients per year will develop AML. The prognosis is poor for many patients, such as the elderly, because they are often unable to tolerate the intensive treatments currently used to treat the disease. The average five-year survival rate of AML patients in the US was 27% in the period 2007-2013.

About MIV-828

MIV-828 is a nucleotide prodrug that has been optimised for the treatment of AML and other hematological malignancies such a myelodysplastic syndrome and T-cell lymphoma. It has been specifically designed to overcome key resistance mechanisms that can limit the effectiveness of other nucleoside analogues, e.g. cytarabine, that are currently used to treat AML.

About Medivir

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleosides and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, which has completed phase II, birinapant in combination with Keytruda® for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase II extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/medivir/r/medivir-nominates-miv-828-as-a-candidate-drug-for-the-treatment-of-hematological-malignancies,c2678010

The following files are available for download:

http://mb.cision.com/Main/652/2678010/948886.pdf

Press release (PDF)

 

View original content:http://www.prnewswire.com/news-releases/medivir-nominates-miv-828-as-a-candidate-drug-for-the-treatment-of-hematological-malignancies-300754145.html

SOURCE Medivir

PR Newswire
www.prnewswire.com

Last updated on: 21/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.